InspireMD, Inc. (NSPR) — Inside-Filings

Kritische 8-K Meldungen

WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (04.03.2026)

Datum	Meldung	Schwere	Filing	Auszug
04.03.2026	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
19.12.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangem
08.09.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Election of Directors On July 31, 2025, InspireMD, Inc. (the “Company”) filed a Current Report on
06.10.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer
21.07.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Stammdaten

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Unternehmen & Branche

Name	InspireMD, Inc.
Ticker	NSPR
CIK	0001433607
Boerse	US
Sektor	Healthcare
Industrie	Medical - Devices
SIC	3841 · Surgical & Medical Instruments & Apparatus

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	54,8 Mio. USD
Beta	0,94
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	8,979,000	-48,786,000	-0.76	69,404,000	55,201,000
2025-09-30	10-Q	2,523,000	-12,708,000	-0.17	78,472,000	64,114,000
2025-06-30	10-Q	1,778,000	-13,151,000	-0.26	33,342,000	20,243,000
2025-03-31	10-Q	1,529,000	-11,166,000	-0.22	38,672,000	28,345,000
2024-12-31	10-K	7,009,000	-32,005,000	-0.76	46,807,000	36,086,000
2024-09-30	10-Q	1,810,000	-7,890,000	-0.16	50,481,000	41,351,000
2024-06-30	10-Q	1,739,000	-7,909,000	-0.22	55,659,000	46,763,000
2024-03-31	10-Q	1,511,000	-7,032,000	-0.21	42,028,000	35,087,000
2023-12-31	10-K	6,205,000	-19,916,000	-0.82	47,643,000	39,501,000
2023-09-30	10-Q	1,556,000	-5,178,000	-0.15	50,020,000	43,257,000
2023-06-30	10-Q	1,649,000	-5,077,000	-0.24	53,638,000	46,813,000
2023-03-31	10-Q	1,239,000	-4,256,000	-0.53	19,921,000	13,426,000
2022-12-31	10-K	5,171,000	-18,491,000	-2.35	24,653,000	17,393,000
2022-09-30	10-Q	1,431,000	-4,529,000	-0.58	28,061,000	21,870,000
2022-06-30	10-Q	1,531,000	-4,636,000	-0.59	32,766,000	25,742,000
2022-03-31	10-Q	1,183,000	-4,481,000		35,171,000	29,704,000
2021-12-31	10-K	4,495,000	-14,918,000		39,712,000	33,532,000
2021-09-30	10-Q	1,071,000	-4,071,000		42,606,000	37,063,000
2021-06-30	10-Q	1,038,000	-3,507,000		46,375,000	40,830,000
2021-03-31	10-Q	1,006,000	-3,243,000		48,635,000	43,954,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-02-02	Gleason Shane Thomas	Officer, Chief Commercial Officer	Open Market Sale	-2,000	1.60	-3,208.00	-14,7%
2026-01-30	Gleason Shane Thomas	Officer, Chief Commercial Officer	Open Market Sale	-2,900	1.63	-4,729.90	-21,7%
2026-01-29	Gleason Shane Thomas	Officer, Chief Commercial Officer	Open Market Sale	-5,000	1.65	-8,250.00	-37,9%
2026-01-28	Gleason Shane Thomas	Officer, Chief Commercial Officer	Open Market Sale	-12,395	1.65	-20,464.15	-94,1%
2026-01-27	Gleason Shane Thomas	Officer, Chief Commercial Officer	Open Market Sale	-4,781	1.66	-7,955.58	-36,6%
2026-01-22	Gleason Shane Thomas	Officer, Chief Commercial Officer	Open Market Sale	-8,411	1.57	-13,238.91	-60,9%
2026-01-21	Gleason Shane Thomas	Officer, Chief Commercial Officer	Open Market Sale	-17,593	1.62	-28,553.44	-131,2%
2026-01-20	Gleason Shane Thomas	Officer, Chief Commercial Officer	Open Market Sale	-2,955	1.59	-4,710.27	-21,7%
2026-01-16	Gleason Shane Thomas	Officer, Chief Commercial Officer	Open Market Sale	-2,250	1.61	-3,627.00	-16,7%
2026-01-15	Gleason Shane Thomas	Officer, Chief Commercial Officer	Open Market Sale	-2,909	1.58	-4,593.31	-21,1%
2025-12-09	Stuka Paul	Director	Open Market Purchase	2,710	1.81	4,905.10	+22,5%
2025-12-09	Stuka Paul	Director	Open Market Purchase	5,073	1.81	9,182.13	+42,2%
2025-12-05	Stuka Paul	Director	Open Market Purchase	5,073	1.86	9,435.78	+43,4%
2025-12-04	Stuka Paul	Director	Open Market Purchase	10,130	1.85	18,740.50	+86,1%
2025-11-12	Stuka Paul	Director	Open Market Purchase	13,431	1.62	21,758.22	+100,0%
2025-07-30	Kester Thomas J	Director	Open Market Purchase	30,991	2.42	74,998.22	+344,7%
2025-07-30	ROUBIN GARY S	Director	Open Market Purchase	41,322	2.42	99,999.24	+459,7%
2025-07-30	Stuka Paul	Director	Open Market Purchase	20,661	2.42	49,999.62	+229,8%
2025-07-30	Slosman Marvin	Director, Officer, CEO and President	Open Market Purchase	10,330	2.42	24,998.60	+114,9%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.